News

The study found that there has been a significant increasing trend in patients with migraine—irrespective of aura status—having an ischemic stroke.

Sodium oxybate is the first therapy approved to treat cataplexy or excessive daytime sleepiness in pediatrics with narcolepsy 7 years of age and older.

Despite the explosion of preventive medications for migraine, a large need for acute care remains.

The Sidney Carter Professor of Neurology at Columbia University Medical Center spoke about the 127 year history of spinal muscular atrophy and how basic science has led to exciting developments.

Customizing injection sites and amounts of botulinum toxin for different presentations of essential hand tremor has been shown to avoid hand weakness.

Heidbreder further described the current understanding of the condition and what she and her colleagues have found out.

For the director of the Johns Hopkins Multiple Sclerosis Center, a biomarker is perhaps only as useful as the clinician community’s ability to read out its measurements.

With many advancements in treatments occurring in recent years, the president of the American Headache Society urged for further research to continue to light the way.

Neurology News Network for the week of Oct. 27, 2018.

The authors suggested that the detection and tracking of seizure cycles on a patient-specific basis should be standard in epilepsy management practices.

The Psychiatrist at Psychiatric Services Solothurn and University of Basel discussed how heart rate variability correlates with sleep stages, which may indicate nocturnal brain activity.

A phase 2 trial demonstrating a PDE-10A inhibitor to be safe but not efficacious for Huntington disease could be followed with the testing of a higher dose.

Allergan is planning a 2019 NDA submission to the FDA for its agent, ubrogepant, based on a pair of new trials.

Symptoms of sudden onset of headache and decreased balance three days earlier prompted a visit to the emergency department.

Within the defined amyloid-tau-neurodegeneration framework of Alzheimer disease, the investigational agent has displayed a hopeful effect on all 3 pieces.

Despite some mistrusting the abilities of imaging to aid in therapeutic development, a new MRI method could better inform the anatomical understanding of the striatum.

Botulinum toxin was found to improve restless leg syndrome in the largest, well-controlled study of the investigational intervention to date.

The approval and immediate launch of the product in both tablet and oral suspension offer a generic alternative to Onfi.

Under treatment, the dynamic of REM sleep related heart rate variability shows early changes during the first week, providing a promising biomarker of treatment.

New brain stimulation technology is proven effective for Parkinson in the first double-blind, sham-controlled trial of this type of intervention.

The current president of the American Neurological Association specifically mentioned the work some groups are doing with small molecule imaging methods to help with this issue.

ITI-214 showed favorable safety with early signs of improvement in motor symptoms for patients with Parkinson disease

The director of the Center of Neurogenetics at Weill Cornell Medicine spoke about the wealth of improvements that have really turned this area of medicine into a much more hopeful one.

The Associate Clinical Professor at the University of South Carolina School of Medicine and Chief Medical Officer at SleepMed emphasized that clinicians need to recognize the impact of sleepiness in terms of quality of life.

"If Mom would just let me play video games again, I would feel better.”

The CGRP inhibitors are poised to transform the treatment paradigm for patients with migraine and cluster headache.

The Global Medical Lead for Migraine and Headache at Teva Pharmaceuticals, the therapy’s developer, discussed its performance in patients with medication overuse headache.

VY-AADC01 demonstrated promising early signs of activity and safety for patients with Parkinson disease.